Ibvilda M 1000 Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, thereby promoting glucose-dependent insulin secretion and reducing glucagon release. The synergistic action of these agents helps in achieving better glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Ibvilda M 1000 is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications. It is contraindicated in patients with renal impairment, hepatic dysfunction, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low but may increase when combined with other antidiabetic agents. Regular monitoring of blood glucose levels, renal function, and liver enzymes is recommended during therapy. Patient adherence to prescribed dosage and lifestyle interventions is essential to optimize therapeutic outcomes and minimize complications associated with type 2 diabetes.